摘要
目的观察单药口服替吉奥治疗老年晚期胃癌的近期临床效果和不良反应的发生情况。方法将62例老年晚期胃癌患者随机分成替吉奥组36例和对照组26例。替吉奥组采用替吉奥胶囊(S-1)单药口服治疗,对照组采用FOLFOX4方案化疗,治疗3个周期后评估和比较两组的临床疗效及不良反应。结果两组治疗有效率(25.0% vs. 26.9%)及1年生存率(47.20% vs. 53.8%)比较差异均无统计学意义(P>0.05);但替吉奥组生活质量的改善率明显高于对照组(33.3% vs. 11.5%,P<0.05);对照组不良反应的发生率明显高于替吉奥组(P<0.05),周围神经毒性仅见于对照组。结论口服替吉奥治疗老年晚期胃癌的近期疗效与FOLFOX4方案相当,但较其更安全。
Objective To evaluate the clinical efficacy and toxicity of Tegafer Gimeracil Oteracil Potassium （S-1） in the treat- ment of elderly patients with advanced gastric cancer. Methods 62 cases of elderly advanced gastric cancer were randomly divided into two groups： the S-1 group （n=36） and the control group （n=26）. The S-1 group was only treated with S-1 twice daily, and the control group was treated by FOLFOX4. The effect and toxicities in the two groups were analyzed after three cycles of chemotherapy. Results No significant difference was observed in response rate （25.0% vs. 26.9%） and one-year survival rate （47.20% vs. 53.8 %） between the two groups. But the improvement rate of quality of hfe was significantly higher in S-1 group than in the control group, and the adverse reaction rate was lower in S-1 group than in control group. Peripheral neurotoxicity was only observed in the control group. Conclusion The S-1 had an equivalent clinical efficacy to FOLFOX4 regimen in the treatment of elderly patients with advanced gastric cancer, but it was safer than FOLFOX4 regimen.
出处
《肿瘤药学》
CAS
2013年第5期378-381,共4页
Anti-Tumor Pharmacy
